CURRENT APPROACHES AND NEW RESEARCH IN
MODERN SCIENCES
International scientific-online conference
85
LASER-ASSISTED TREATMENT OF ORAL MUCOSAL DISEASES IN
PATIENTS WITH CHRONIC RENAL FAILURE: CLINICAL OUTCOMES
AND EVIDENCE-BASED RECOMMENDATIONS
Sabirov Bobur Kadirbaevich
Khabibova Nazira Nasullaevna
Bukhara State Medical Institute
https://doi.org/10.5281/zenodo.15754006
Abstract:
Oral mucosal diseases are prevalent among patients with chronic
kidney disease (CKD) and are often complicated by oxidative stress and immune
dysregulation. This study evaluates the clinical outcomes of integrating low-level
laser blood irradiation (LLLI) with conventional antiseptic therapy in the
management of oral inflammatory conditions in CKD patients. The prospective
controlled trial included 100 CKD patients with chronic inflammatory oral
lesions, divided into a control group receiving standard antiseptic therapy and a
main group additionally treated with LLLI and immunomodulatory antiseptics.
Clinical assessments, along with biochemical and immunological parameters,
were used to evaluate treatment efficacy. The results demonstrated superior
outcomes in the LLLI group, including improved epithelial healing, reduced
recurrence, and enhanced biochemical markers, supporting the integration of
LLLI into standard care protocols.
Keywords:
chronic kidney disease, oral mucosal disease, laser therapy,
inflammation, immunomodulation, clinical dentistry, antiseptic treatment,
cytokines
Introduction:
Chronic kidney disease (CKD) leads to systemic
complications that adversely affect the oral cavity. Oral mucosal inflammation,
characterized by erythema, ulceration, and chronic discomfort, is frequently
observed in CKD patients. These manifestations are linked to reduced salivary
flow, altered electrolyte balance, and impaired immune responses. Traditional
treatment approaches rely on antiseptic and symptomatic therapy; however,
recurrence and prolonged healing remain clinical challenges.
Low-level laser therapy (LLLT), particularly laser blood irradiation, has
shown promise in improving microcirculation, stabilizing cellular membranes,
and modulating oxidative stress and inflammation. By enhancing endogenous
antioxidant defense and promoting cytokine balance, LLLT may serve as a
valuable adjunct in treating oral conditions in immunocompromised patients,
including those with CKD.
CURRENT APPROACHES AND NEW RESEARCH IN
MODERN SCIENCES
International scientific-online conference
86
This study explores the practical application, clinical efficacy, and systemic
impact of combining LLLT with antiseptic therapy for oral mucosal diseases in
CKD patients.
Materials and Methods:
A total of 100 adult CKD patients with diagnosed
chronic inflammatory oral mucosal conditions (e.g., gingivitis, stomatitis,
ulcerative lesions) were enrolled and randomly assigned to two groups:
Control group (n=50): Received standard topical antiseptic treatment and
anti-inflammatory agents.
Main group (n=50): Received the same treatment plus low-level laser
blood irradiation (LLLI) and an immunomodulatory antiseptic.
Clinical Inclusion Criteria:
Age 30–65 years
CKD stages 3–5 (on conservative or dialysis therapy)
Non-smoking and non-diabetic status
Absence of systemic immunosuppressive therapy
Treatment Protocol:
LLLI: Intravenous laser irradiation using a 635 nm wavelength, 10
minutes/session, 10 sessions over 2 weeks
Antiseptics: Chlorhexidine and lysozyme-based rinses used three times
daily for 14 days
Clinical Assessment: Mucosal healing, lesion regression, recurrence rate at
30 and 60 days post-treatment
Laboratory Measures: Lipid peroxidation (LOOH), catalase activity,
cytokines (IL-1β, IL-6, IL-2)
Statistical Evaluation: Data were analyzed using STATISTICA 6.0. Student's
t-test and Chi-square test were applied. A p-value <0.05 was considered
statistically significant.
Results:
Clinical Findings: Patients in the main group showed faster
epithelial healing, with average recovery in 5.7 ± 1.2 days, compared to 9.3 ± 1.8
days in the control group (p<0.001). Pain intensity measured using the Visual
Analog Scale (VAS) decreased more rapidly in the main group (from 6.8 to 1.2)
versus the control group (from 6.6 to 2.9).
At 30 days post-treatment, recurrence of lesions occurred in 18% of control
patients versus only 6% in the main group. At 60 days, these figures were 30%
and 12%, respectively, indicating sustained benefits of laser therapy.
Biochemical Markers:
CURRENT APPROACHES AND NEW RESEARCH IN
MODERN SCIENCES
International scientific-online conference
87
LOOH: Decreased from 2.91 ± 0.11 to 1.48 ± 0.07 in the main group
(p<0.001), compared to 2.89 ± 0.12 to 2.05 ± 0.09 in the control group (p<0.05)
Catalase: Increased from 9.01 ± 0.65 to 16.23 ± 0.79 in the main group
(p<0.01), versus 8.94 ± 0.62 to 12.87 ± 0.84 in the control group (p<0.05)
Cytokine Regulation:
IL-1β: Reduced from 5.47 ± 0.42 to 3.06 ± 0.21 in the main group (p<0.01),
vs. 5.41 ± 0.39 to 4.32 ± 0.27 in controls (p<0.05)
IL-6: Reduced from 5.93 ± 0.48 to 2.79 ± 0.26 in the main group (p<0.001),
vs. 5.88 ± 0.51 to 4.12 ± 0.35 in controls (p<0.05)
IL-2: Increased from 5.57 ± 0.46 to 9.82 ± 0.61 in the main group (p<0.01),
vs. 5.62 ± 0.49 to 7.98 ± 0.54 in controls (p<0.05)
Discussion:
The results clearly support the clinical utility of integrating
LLLT into treatment protocols for oral mucosal diseases in CKD patients. Faster
mucosal regeneration, significant pain relief, and lower recurrence rates suggest
that LLLT enhances the healing microenvironment and systemic resilience. The
improvements in LOOH and catalase indicate a reversal of oxidative stress, while
favorable cytokine shifts suggest restored immune competence.
These findings align with the growing div of evidence supporting LLLT in
systemic and localized inflammatory conditions. For CKD patients, in whom
healing is typically compromised, such interventions can be life-enhancing.
Recommendations:
Integrate LLLT into standard care protocols for oral lesions in CKD units
and dental clinics
Use immunomodulatory antiseptics alongside LLLT to maximize local and
systemic benefits
Monitor oxidative stress and cytokine profiles in high-risk patients for
personalized therapy
Conclusion:
Laser-assisted therapy offers a safe, effective, and evidence-
based strategy for managing oral mucosal diseases in CKD patients. It
significantly improves clinical recovery and modulates systemic inflammation,
justifying its integration into routine multidisciplinary care.
References:
1.
Zeng X. et al. (2021). The Role of Oxidative Stress in Oral Diseases.
International Journal of Molecular Sciences, 22(16), 8970.
2.
Giannobile W.V., Lang N.P. (2019). Antioxidants and periodontal disease.
Journal of Periodontology, 90(5), 541–548.
3.
Lushchak V. (2019). Free radicals, reactive oxygen species, oxidative stress
and its classification. Chemico-Biological Interactions, 301, 37–49.
CURRENT APPROACHES AND NEW RESEARCH IN
MODERN SCIENCES
International scientific-online conference
88
4.
Kim J.J., Kim Y.S. (2020). The role of inflammatory cytokines in the
pathogenesis of oral diseases. Journal of Oral Pathology and Medicine, 49(9),
851–859.
5.
Zhang L., Sun X. (2021). The effect of low-level laser therapy on oxidative
stress and inflammation in oral diseases. Photomedicine and Laser Surgery,
39(2), 85–91.
6.
Moskvin S.V. (2021). Laser therapy in dentistry: mechanisms and clinical
effectiveness. Voprosy sovremennoy stomatologii, (1), 12–19.
7.
Brusilovskiy D.B., Kryukov A.Yu. (2018). Immune and metabolic disorders
in patients with chronic kidney failure. Klinicheskaya meditsina, (5), 41–45.
8.
Kostienko L.A., Panchenko Yu.V. (2020). Cytokine profile dynamics in
patients with oral mucosal diseases against systemic disorders. Sovremennaya
stomatologiya, (3), 24–28.
9.
Borovsky E.V., Leontyev V.K. (2017). Biological foundations of clinical
dentistry. Moscow: Meditsina, 512 p.
10.
Shevchenko A.V., Grishin D.V. (2019). The impact of chronic renal failure
on periodontal tissue condition. Klinicheskaya stomatologiya, (2), 18–22.
